Author

William H. Zammit

Bicycle Therapeutics (United Kingdom)Primary ORCID profile (0000-0001-9104-2078 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

William H. ZammitiD1 paper · Manchester Academic Health Science Centre

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexandra Rezvaya· 1 shared Ben J. F. Blakeman· 1 shared Christopher J. Leitheiser· 1 shared Fay J. Dufort· 1 shared G.A. BezerraiD· 1 shared Gemma MuddiD· 1 shared Kathleen Q.W. Ho· 1 shared Kevin A. McDonnelliD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexandra Rezvaya

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Conditional activation of NK cell function using chemically synthetic constrained bicyclic peptides directed against NKp46 and tumor-expressed antigens

Fay J. Dufort, Christopher J. Leitheiser, Alexandra Rezvaya, Tucker Ezell, Kathleen Q.W. Ho, G.A. Bezerra, Ben J. F. Blakeman, Sandra Uhlenbroich, William H. Zammit, Lukas Stanczuk, Peter de Nully Brown, Gemma Mudd, Kevin A. McDonnell, Nicholas Keen, Philip E. Brandish

This paper develops synthetic peptides that activate NK cells to kill tumor cells by binding to NKp46 and tumor antigens, leading to cytokine secretion and enhanced anti-tumor immunity.

bioRxiv · Oct 30, 2024 · PreprintCancer Biology